
    
      This is a Phase 2, open-label, outcomes-assessor masked, multicentre, randomised, controlled
      study to evaluate the safety and efficacy of two doses of GT005 administered as a single
      subretinal injection in subjects with GA secondary to AMD.

      The trial includes a screening period of up to 8 weeks and a 96-week study period.

      Subjects will be randomised to one of two groups; GT005 or the untreated control group.
    
  